Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Abasaglar® (insulin glargine): Use With COVID-19 Vaccines
The use of vaccines against SARS-CoV-2 in patients treated with Abasaglar has not been studied.
Administration of COVID-19 Vaccines to Patients Receiving Abasaglar
Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the COVID-19 pandemic. Recently, vaccines have been developed against SARS-CoV-2 and some of them are already available.1-4
SARS-CoV-2 Vaccination With Abasaglar
The use of a SARS-CoV-2 vaccine in patients treated with Abasaglar has not been studied by Lilly.
Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with Abasaglar should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient and the risks and benefits of vaccination.
Possible impact of vaccination on blood glucose concentration
The International Diabetes Federation IDF states that after any vaccination the blood glucose levels might rise for a few days.5
Further resources on COVID-19 Vaccines and Diabetes
For information on COVID-19 vaccines and diabetes, please refer to
1Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y
2Jackson LA, Anderson EJ, Rouphael NG, et al; mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920-1931. https://doi.org/10.1056/NEJMoa2022483
3COVID-19 vaccines. Centers for Disease Control and Prevention. Updated December 31, 2020. Accessed January 4, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html
4Draft landscape of COVID-19 candidate vaccines. World Health Organization (WHO). November 12, 2020. Accessed December 4, 2020. https://www.who.int/docs/default-source/blue-print/novel-coronavirus-landscape-covid-19-(7).pdf?sfvrsn=a4e55ae3_2&download=true
5International Diabetes Federation Europe. Diabetes & Coronavirus Vaccination. https://idf.org/our-network/regions-members/europe/europe-news/370-diabetes-coronavirus-vaccination.html. Accessed April 29, 2021
6Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19
7International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html. Accessed March 18, 2020
8COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china
Abasaglar = Abasaglar® (insulin glargine) 100 units/mL
COVID-19 = coronavirus disease 2019
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
Date of Last Review: 04 January 2021